Cutaneous leishmaniasis and iron metabolism: current insights and challenges.

Leishmaniasis is a vector-borne parasitic infection induced by protozoa of the genus The disease spectrum ranges from skin lesions to visceral leishmaniasis, which is fatal if untreated. The cutaneous leishmaniasis is characterized by a clinical polymorphism of lesions with a broad range of severity ranging from a self-limited lesion to multiple disfiguring lesions stigmatizing the patient for life. Although iron is required for several process of infection including survival, growth and virulence, the number of studies on host iron metabolism during this infection remains limited.

Inhibiting Human and Arginases Using as a Potential Therapy for Cutaneous Leishmaniasis: A Molecular Docking Study.

Cutaneous leishmaniasis (CL), a vector-borne parasitic disease caused by the protozoan, is a serious public health problem in Morocco. The treatment of this disease is still based on pentavalent antimonials as the primary therapy, but these have associated side effects. Thus, the development of effective, risk-free alternative therapeutics based on natural compounds against leishmaniasis is urgent.